Nurix Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Its Phase 1 Clinical Trial Cancer Data for BTK Degrader NX-5948.

BenzingaDec 2 08:43 ET

Nurix Therapeutics Announces Webcast To Review New Data From Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

GlobeNewswireDec 2 07:00 ET

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswireNov 25 07:00 ET

Sector Update: Health Care Stocks Rise Pre-Bell Thursday

MT NewswiresNov 21 09:13 ET

Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe

MT NewswiresNov 20 17:45 ET

Nurix Therapeutics Receives PRIME Designation From the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

GlobeNewswireNov 20 16:00 ET